Dihexa

Mechanism

An extremely potent cognitive-enhancing peptide, reportedly 10 million times more potent than BDNF at promoting nerve connections. It was designed to mimic the brain-protective effects of angiotensin IV. Primarily used for cognitive enhancement and potential neurodegenerative disease applications. Very early stage — mostly animal research.

Effects

## Detailed Effects — Dihexa ### Central Nervous System — Cognitive Enhancement [Tier 2-3] - Synthetic angiotensin IV analog: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Small, orally bioavailable, and blood-brain barrier penetrant. - Mechanism: allosteric activator of the hepatocyte growth factor (HGF)/c-Met receptor system. Does NOT directly bind c-Met but stabilizes HGF in an active conformation, augmenting endogenous HGF/c-Met signaling. - HGF/c-Met signaling promotes: dendritic spine formation, synaptogenesis, long-term potentiation (LTP), and neuronal survival. - **Potency claim**: 10 million times (10^7) more potent than BDNF at promoting synaptic connections in hippocampal neuron cultures — this figure comes from the McCoy et al. (2013) study comparing picomolar Dihexa to nanomolar BDNF concentrations for spinogenesis. - **Animal cognitive studies**: Reversed scopolamine-induced cognitive deficits in rats (cholinergic blockade model). Improved spatial learning in water maze. Improved cognitive function in a hepatic encephalopathy model. - Proposed to enhance memory consolidation, learning speed, verbal fluency, and executive function in humans — but NO human clinical trials exist. ### Potential Oncological Concern [Tier 2-3] - HGF/c-Met pathway is a well-known oncogenic signaling axis. c-Met is overexpressed in many cancers (breast, lung, gastric, hepatocellular, renal). - Chronic activation of HGF/c-Met could theoretically promote tumor growth, invasion, and metastasis in susceptible individuals. - This is the MAJOR safety concern with Dihexa — it is activating a pathway that pharmaceutical companies are trying to INHIBIT in cancer patients (c-Met inhibitors: capmatinib, tepotinib, crizotinib). - No long-term safety studies exist. Risk is theoretical but biologically plausible. ### Peripheral Effects [Tier 3] - HGF/c-Met signaling also promotes wound healing, liver regeneration, and kidney repair — Dihexa may have regenerative potential beyond the CNS. - Potential for peripheral nerve regeneration (HGF promotes Schwann cell proliferation).

Practitioner Guide

## Practitioner Guide — Dihexa ### Regulatory Status & Safety Warning - NOT FDA-approved. NO human clinical trials. All dosing is extrapolated from animal models and community anecdotal reports. - Available from research peptide suppliers as capsules, sublingual solution, or raw powder. - **MAJOR SAFETY CAVEAT**: The HGF/c-Met pathway is oncogenic. Chronic Dihexa use carries a THEORETICAL risk of promoting cancer growth, especially in individuals with occult malignancies, family history of c-Met-driven cancers, or genetic predisposition. This risk is unquantified. - Use at your own risk. Practitioners who recommend Dihexa must discuss the c-Met/cancer concern with patients. ### Dosing Protocols (Community/Practitioner Anecdotal) **Basic Cognitive Enhancement Protocol** - 10 mg oral or sublingual once daily, morning. - Start at 5 mg for the first 3-5 days to assess tolerance. - Sublingual may provide faster onset and somewhat higher bioavailability than oral. - Cycle: 4-8 weeks ON, minimum 4 weeks OFF. **Advanced Cognitive Protocol** - 20 mg oral or sublingual once daily, morning. - For experienced users who have tolerated 10 mg without issues. - Some users report enhanced effects at 20 mg but also more pronounced "brain fog" upon discontinuation. - Cycle strictly: 4-6 weeks ON, 4-8 weeks OFF. **Microdose Protocol (Conservative)** - 2.5-5 mg oral daily. - Lower dose reduces theoretical c-Met activation concern while still potentially providing cognitive benefits. - Some practitioners prefer this approach given the unknown safety profile. - Can run longer cycles (8-12 weeks) at lower doses. ### What Experienced Users Report - **Positive reports**: Enhanced verbal fluency (words come easier), improved memory recall, better pattern recognition, enhanced learning speed, vivid and detailed dreams. - **Onset**: Subtle cognitive effects noticed within 3-7 days. Full effects at 2-4 weeks. - **Negative reports**: Brain fog upon discontinuation (may last 1-2 weeks), headaches in some users, anxiety or overstimulation at higher doses. - **IMPORTANT**: These are anecdotal community reports, not clinical data. Placebo effects cannot be excluded. ### Stacking Combinations (Advanced Practitioner Protocols) **Cognitive Maximizer Stack (Heavy)** - Dihexa 10-20 mg oral daily - + Cerebrolysin 5-10 mL IM daily (neurotrophic foundation) - + Semax 600-900 mcg intranasal daily (BDNF + dopamine) - + Selank 400 mcg intranasal daily (anxiolytic balance) - This combines c-Met/HGF activation (Dihexa) with broad neurotrophic support (Cerebrolysin) and targeted BDNF/dopamine upregulation (Semax) — multiple complementary pathways. - Run for 10-20 day courses. Not for long-term continuous use. **Memory & Learning Stack (Moderate)** - Dihexa 10 mg oral daily - + Lion's Mane 1-2 g daily (NGF support) - + Phosphatidylserine 300 mg daily - + Bacopa monnieri 300 mg (standardized, 50% bacosides) - Cycle: 8 weeks ON, 4 weeks OFF. ### Pre-Screening Recommendations (Practitioner Consensus) Given the c-Met/cancer concern, practitioners who use Dihexa should consider: - Cancer screening before starting (age-appropriate — mammogram, PSA, colonoscopy, CT chest if smoker). - Family history assessment for c-Met-driven cancers. - Avoid in patients with active cancer or strong family history of cancer. - Avoid in patients on c-Met inhibitor therapy (obvious contraindication). - Limit cycle duration and use the lowest effective dose. ### Storage - Capsules: room temperature, protect from light and moisture. - Sublingual solutions: refrigerate. Protect from light. - Raw powder: store at -20°C with desiccant.

Dosing Protocols

Contraindications & Cautions

• hard stop — Breastfeeding
  No human safety data. Do not use during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Active cancer
  Dihexa activates the hepatocyte growth factor (HGF)/c-Met signaling pathway, which is a major driver of tumor cell proliferation, invasion, and metastasis in many cancers. c-Met is an established oncogene, and HGF/c-Met pathway activation is actively targeted by anticancer drugs. Dihexa could directly promote tumor growth and metastasis.
  Action: Do not use in patients with any active cancer. This is a critical safety concern due to the direct pro-metastatic mechanism of action.
• hard stop — Pregnancy
  No human safety data exists. Research compound with potent neurotrophic activity via HGF/c-Met pathway. Effects on fetal development completely unknown.
  Action: Do not use during pregnancy.
• hard stop — Under 18 years of age
  Research compound with no human safety data. Not for pediatric use.
  Action: Do not provide to individuals under 18.
• caution — General use
  Dihexa has NO human safety data. It is a research compound tested only in animal models. Human pharmacokinetics, toxicology, therapeutic index, and long-term effects are completely unknown. The HGF/c-Met pathway it activates has significant oncogenic potential.
  Action: Use only with full informed consent regarding absence of human safety data and theoretical cancer risk. Medical supervision essential. Regular health monitoring recommended.
• requires physician — History of cancer (in remission)
  Even in cancer survivors, activation of the HGF/c-Met pathway carries meaningful risk of promoting dormant micrometastases or new tumor formation. c-Met overexpression is associated with poor prognosis in many cancer types.
  Action: Requires oncologist evaluation. Risk-benefit must be carefully weighed. Consider alternatives without pro-metastatic mechanisms.

Evidence

• The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system

  Benoist CC, Kawas LH, Zhu M, Bhatt Aparna, Wright JW, Bhatt SP, Harding JW (2014) — Journal of Pharmacology and Experimental Therapeutics — PMID: 24860060

  Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide), an angiotensin IV analog, demonstrated potent procognitive effects in animal models of cognitive impairment at picomolar concentrations. Mechanism involves activation of hepatocyte growth factor (HGF)/c-Met receptor system, promoting synaptogenesis and dendritic spine formation. Effective orally and shown to cross the blood-brain barrier.

  emerging

Research Summary

## Research Summary — Dihexa ### Tier 1: Randomized Controlled Trials - **NO human clinical trials exist** — not even Phase 1 safety studies. This is the most significant evidence gap. ### Tier 2: Preclinical Studies (Animal Data) - **McCoy et al., J Pharmacol Exp Ther 2013**: Characterized Dihexa as an HGF/c-Met activator. Demonstrated procognitive effects in multiple animal models (scopolamine-induced amnesia, hepatic encephalopathy). Picomolar potency for spinogenesis — the "10 million times more potent than BDNF" claim originates from this paper. - **Benoist et al., J Pharmacol Exp Ther 2014**: Confirmed that procognitive and synaptogenic effects are dependent on HGF/c-Met system activation. c-Met inhibitors blocked Dihexa's cognitive effects. - **Wright & Harding (University of Washington State)**: The primary research group behind Dihexa. Published several papers characterizing the angiotensin IV → IRAP → HGF/c-Met signaling pathway. - **Oral bioavailability**: Confirmed in animal models — Dihexa crosses the BBB and is active orally. ### Tier 3: Case Reports & Practitioner Protocols - A growing community of biohackers and nootropic enthusiasts report subjective cognitive enhancement. - Common reports: improved verbal fluency, memory recall, learning speed, vivid dreams. - Some reports of brain fog/cognitive "hangover" upon discontinuation, suggesting possible receptor adaptation or neuroplastic changes that need time to stabilize. - Multiple nootropic forums (Reddit r/nootropics, Longecity) have extensive user experience reports — quality and reliability of these reports varies widely. - Some practitioners at longevity/biohacking clinics include Dihexa in cognitive optimization protocols, typically stacked with Cerebrolysin and Semax. ### Gaps (CRITICAL) - **No human safety data whatsoever**. This is the single biggest concern. - **c-Met oncogenic risk is unquantified**. This pathway is actively targeted for INHIBITION by oncology drugs. - **No pharmacokinetic data in humans** — bioavailability, half-life, metabolism, drug interactions all unknown. - **No dose-response data in humans** — all dosing is extrapolated from rat studies and guesswork. - **Long-term effects completely unknown** — neuroplastic effects from chronic c-Met activation could be irreversible. - The research group (Wright & Harding) has not published since ~2014, and no pharmaceutical company has picked up Dihexa for clinical development. ### Active Trials - None registered on ClinicalTrials.gov. No pharmaceutical company has initiated human trials for Dihexa as of 2026.